Orexo appoints Robin Evers to its Board of Directors

– SWEDEN, Fyrislund –  Orexo AB, (STO: ORX | OTC: ORXOY) today announced the appointment of Robin Evers to its Board of Directors, replacing Henrik Kjaer Hansen, who will resign after having represented the largest shareholder, Novo Holdings A/S, since 2018.

Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo.

About Robin Evers

Robin Evers is SVP and Head of Global Regulatory Affairs and global Safety, Medical Writing, and R&D Quality, at Novo Nordisk A/S, and has more than 25 years of experience in the pharmaceutical industry, with expertise in the development of biologics, vaccines, and small molecule drugs from leading positions at Wyeth, Pfizer and since 2013 at Novo Nordisk A/S in Denmark. At Novo Nordisk A/S, Robin Evers is a member of the global R&D management team and has been instrumental in curating international strategies to support the development and registration of innovative and well-differentiated products, such as the peptide medicines Ozempic, Wegovy, and Rybelsus.

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm’s main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information: https://www.orexo.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.